ABU DHABI, UAE, Aug. 30, 2024 /PRNewswire/ -- Ferrari World Yas Island, Abu Dhabi hosted an exclusive preview event on August 29 ahead of the launch of the world's first Ferrari-themed Esports Arena which is set to officially open to the public in September 2024. The award-winning theme park celebration featured VIPs, media, influencers, and other distinguished guests.
To view the Multimedia News Release, please click:  
https://www.multivu.com/players/uk/9287851-ferrari-world-yas-island-hosts-preview-event-ahead-launch-ferrari-themed-esports-arena/
The launch event had guests on the edge of their seats with thrilling live entertainment. Now, F1 fans and adrenaline junkies can immerse themselves in the ultimate racing experience at the Ferrari-themed Park. The arena boasts 20 Gran Turismo simulators, including 14 for adults and 6 designed for younger guests, ensuring fun for the whole family. Adding a further element of thrills, there are three F1 simulators that allow participants to feel the rush of driving a real Ferrari race car on a F1 Grand Prix circuit. Additionally, Ferrari World Abu Dhabi remains committed to inclusivity with two GT simulators specifically designed to accommodate people of determination.
Theme Park entry tickets include access to the GT simulators until year end, while the F1 simulators are available at an additional fee starting from AED 60 per race.
For more information please visit: www.ferrariworldabudhabi.com.
About Ferrari World Yas Island, Abu Dhabi:
Ferrari World Yas Island, Abu Dhabi, the award-winning Ferrari-inspired theme park operated by Miral Experiences, opened its doors to fans in 2010. The theme park celebrates the spirit of the legendary marque and is home to numerous thrilling rides, family-friendly attractions, state-of-the-art simulators, live shows, as well as popular seasonal events and festivities that bring together extraordinary performances from around the globe. Ferrari World Yas Island, Abu Dhabi is home to the world's fastest roller coaster, Formula Rossa, as well as record-breaking roller coaster Flying Aces and the most immersive mega-coaster Mission Ferrari.
In 2020, Ferrari World Yas Island, Abu Dhabi launched the all-new Roof Walk experience for guests seeking a thrilling adventure. Additionally, the Park welcomed the state-of-the-art Family Zone. Designed to entertain guests of all ages, the Family Zone features four miniature versions of the theme park's most iconic, record-breaking rides for the entire family to enjoy.
Since its inception, Ferrari World Yas Island, Abu Dhabi has been recognized by several leading industry awards garnering over 60 regional and international accolades. Most recently, the park was named 'World's Leading Theme Park' for the fifth consecutive year by the World Travel Awards and Mission Ferrari won the title of 'Thrills' at the 2023 Blooloop Innovation Awards along with 'Best Theme Park" at the 2023 MENALAC Awards and won a Gold Stevie Award in 2023.
For more information, please visit: www.ferrariworldabudhabi.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Ferrari World Yas Island Abu Dhabi hosts an Exclusive Preview Event ahead of the launch of The World's First Ferrari-themed Esports Arena
NANJING, China, Sept. 14, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Ischemic Stroke (AIS). Sanbexin sublingual tablets is the first innovative drug in the world to be designated with the Breakthrough Therapy by the FDA for the treatment of stroke.
The Breakthrough Therapy designation stems from the provisions of 《Food and Drug Administration Safety and Innovation Act》. It is designed to expedite the development and regulatory review of drugs for treating serious diseases and addressing significant unmet medical needs. The designation will be beneficial for the drugs to obtain the FDA's guidance in the clinical development, accelerate the overseas clinical development process, and is also expected to significantly shorten the time for marketing review through the priority review designation.
The Breakthrough Therapy designation is based on the significant improvement in efficacy metrics demonstrated by the sublingual tablets in a previous clinical study. The data from a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical study in China for the treatment of AIS demonstrated that Sanbexin sublingual tablets significantly improved neurological recovery and independent living ability in patients with AIS compared to placebo, meeting the expected efficacy endpoints with a favorable safety profile. JAMA Neurology published the study's key findings online.
The designation will be beneficial for Simcere to obtain the FDA's guidance in the clinical development of Sanbexin sublingual tablets, accelerate the overseas clinical development process, and is also expected to significantly shorten the time for marketing review through the priority review designation.
According to a recent article in The Lancet, stroke is the second leading cause of death and disability worldwide, with 12 million new cases and 6.6 million deaths each year. Among them, acute ischemic stroke is the most common type of stroke, accounting for about 70% of all strokes, and constituting a heavy disease burden for all countries around the world. The efficacy of acute ischemic stroke treatment is highly time-dependent. Receiving treatment as early as possible will help patients to improve their disease outcome and avoid disability.
Sanbexin sublingual tablets is a brain cytoprotective agent composed of edaravone and dexborneol, two active ingredients with synergistic anti-oxidant and anti-inflammatory effects, which can significantly reduce brain cell injury or impairment caused by AIS. Such unique sublingual formulation can quickly disintegrate once in contact with the saliva once place under the tongue and can be absorbed into the blood through the sublingual venous plexus, which is expected to increase the flexibility of stroke treatment. Sequential therapy consisting of the marketed Sanbexin concentrated solution for Injection. These two formulae enable patients to receive a complete course of treatment in and outside of the hospital.
On June 28, 2023, the new drug application (NDA) for Sanbexin sublingual tablets in China is accepted by the National Medical Products Administration. The first indication is for the improvement of neurological symptoms, daily activities, and functional impairment due to AIS. Phase I clinical trials for Sanbexin sublingual tablets on healthy volunteers have been completed in the United States.
CONTACT: Haoyun Huang, huanghaoyun@simcere.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration
